リンパ球サブセットに基づく非侵襲的バイオマーカーは,EGFR-TKIで前治療されたEGFR変異性NSCLCにおける免疫化学療法の有効性を予測する

Lianxi Song1,2,3, Liang Zeng1, Qinqin Xu4

  • 1Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China.

iScience
|August 20, 2025
PubMed
まとめ

免疫チェックポイント阻害剤 (Chemo+ICI) と併用した化学療法は,チロシンキナーゼ阻害剤に耐性のあるEGFR変異性非小細胞肺がん患者にとって有意に有益である. 新しいリンパ球サブセットモデル (LSM) は,この組み合わせ治療に対する患者の反応を予測できます.

関連する概念動画

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K